<DOC>
	<DOCNO>NCT00275210</DOCNO>
	<brief_summary>To evaluate FOLFOX regimen versus LV5FU2 adjuvant treatment stage II III colon cancer . Primary objective : Disease Free Survival ( DFS ) Secondary objective : Overall Survival ( OS ) , safety ( include long term toxicity )</brief_summary>
	<brief_title>MOSAIC - Multicenter International Study Oxaliplatin/ 5FU-LV Adjuvant Treatment Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Main selection criterion : Histologically proven stage Dukes `` B2 `` ( stage II : T3T4 N0 M0 ) `` C `` ( stage III : T N12 M0 ) colon carcinoma . The inferior pole tumor must peritoneal reflection ( &gt; 15 cm anal margin ) · Complete resection primary tumor without gross microscopic evidence residual disease Treatment within 7 week follow surgery Age 1875 year old ECOG PS £ 2 No prior chemo , immuno radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Oxaliplatin</keyword>
	<keyword>Chemotherapy , adjuvant</keyword>
	<keyword>Colonic Neoplasms</keyword>
</DOC>